FAS LIGAND VARIANT AND RECOMBINANT CELL HAVING INCREASED CYTOTOXICITY AND GREATER SURVIVAL

Herein is disclosed variants of Fas ligand (APTL; FASL; CD178; CD95L; ALPS1B; CD95-L; TNFSF6; TNLG1A; APT1LG1) and vectors providing thereof. Further, herein is disclosed a recombinant cell, such as NK cell (natural killer cell), comprising genetic elements allowing production of at least one FasL v...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BELETSKY, Igor, GLUKHOVA, Xenia
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Herein is disclosed variants of Fas ligand (APTL; FASL; CD178; CD95L; ALPS1B; CD95-L; TNFSF6; TNLG1A; APT1LG1) and vectors providing thereof. Further, herein is disclosed a recombinant cell, such as NK cell (natural killer cell), comprising genetic elements allowing production of at least one FasL variant, to increase the cytotoxicity and survival of the recombinant cell, for improving therapeutic activity of the recombinant cell. Also a pharmaceutical composition comprising the recombinant cell and methods for obtaining thereof, as well as NK cells modified to express the Fas ligand variants for use in immunotherapy are disclosed L'invention concerne des variants du ligand Fas (APTL ; FASL ; CD178 ; CD95L ; ALPS1B ; CD95-L ; TNFSF6 ; TNLG1A ; APT1LG1) et des vecteurs les fournissant. En outre, l'invention concerne une cellule recombinante, telle qu'une cellule NK (cellule tueuse naturelle), comprenant des éléments génétiques permettant la production d'au moins un variant FasL, pour augmenter la cytotoxicité et la survie de la cellule recombinante, pour améliorer l'activité thérapeutique de la cellule recombinante. L'invention concerne également une composition pharmaceutique comprenant la cellule recombinante et des procédés d'obtention de celle-ci, ainsi que des cellules NK modifiées pour exprimer les variants de ligand Fas pour une utilisation en immunothérapie